Clinuvel Pharmaceuticals Limited Stock Deutsche Boerse AG
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.500 EUR | 0.00% |
|
0.00% | -21.43% |
| Market Cap | 476M 336M 291M 272M 249M 469M 32.02B 3.19B 1.25B 16.04B 1.26B 1.24B 53.09B | P/E 2026 * |
13.3x | P/E 2027 * | 12.6x |
|---|---|---|---|---|---|
| Enterprise Value | 223M 158M 137M 128M 117M 220M 15.02B 1.5B 586M 7.53B 592M 580M 24.91B | EV / Sales 2026 * |
2.25x | EV / Sales 2027 * | 1.83x |
| Free-Float |
83.79% | Yield 2026 * |
0.65% | Yield 2027 * | 0.85% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 month | -7.56% | ||
| 3 months | -3.51% | ||
| 6 months | -16.67% | ||
| Current year | -21.43% |
| 1 week | 5.3 |  | 5.5 |
| 1 month | 5.3 | | 6.4 |
| Current year | 5.1 | | 7.39 |
| 1 year | 5.1 | | 7.68 |
| 3 years | 4.8 | | 12.68 |
| 5 years | 4.8 | | 27 |
| 10 years | 3.27 | | 27 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
BRD | Director/Board Member | 63 | 01/11/2005 |
Guy van Dievoet
BRD | Director/Board Member | - | 06/09/2024 |
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | - | - | 336M | |
| +1.59% | +2.85% | +39.32% | +0.52% | 78.32B | |
| +2.77% | +4.78% | -0.98% | +28.10% | 51.1B | |
| -0.84% | +0.09% | +20.92% | +175.02% | 49.18B | |
| -0.13% | +7.42% | -49.33% | -50.09% | 44.71B | |
| +0.80% | +2.46% | +59.13% | -24.15% | 30.72B | |
| +1.84% | +0.87% | +53.80% | +86.83% | 24.44B | |
| +9.86% | +7.94% | +126.53% | -40.68% | 23.62B | |
| +4.29% | +9.40% | +3.95% | +230.49% | 21.05B | |
| +1.66% | -3.70% | +66.13% | +121.72% | 16.61B | |
| Average | +2.18% | +4.08% | +35.50% | +58.64% | 37.75B | |
| Weighted average by Cap. | +1.88% | +4.29% | +26.94% | +44.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.21M 70.1M 60.64M 56.65M 51.91M 97.77M 6.67B 664M 260M 3.34B 263M 257M 11.06B | 105M 73.91M 63.94M 59.73M 54.74M 103M 7.04B 700M 275M 3.53B 277M 271M 11.67B |
| Net income | 35.72M 25.24M 21.83M 20.4M 18.69M 35.2M 2.4B 239M 93.78M 1.2B 94.75M 92.68M 3.98B | 37.66M 26.61M 23.02M 21.5M 19.71M 37.12M 2.53B 252M 98.88M 1.27B 99.9M 97.72M 4.2B |
| Net Debt | -253M -179M -154M -144M -132M -249M -17B -1.69B -663M -8.52B -670M -656M -28.18B | -285M -201M -174M -163M -149M -280M -19.14B -1.9B -747M -9.59B -755M -738M -31.74B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/08/26 | EUR 5.500 | 0.00% | 0 |
| 06/08/26 | EUR 5.500 | +3.77% | 0 |
| 05/08/26 | EUR 5.300 | 0.00% | 0 |
| 04/08/26 | EUR 5.300 | 0.00% | 0 |
| 03/08/26 | EUR 5.300 | -3.64% | 395 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
Select your edition
All financial news and data tailored to specific country editions
